ExpreS2ion’s core platform patent allowed in Canada
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in Canada and will be granted with expiry June 12, 2029.“With the patent allowance in Canada, ExpreS2ion has now successfully obtained patent protection of its ExpreS2 platform in all major markets of interest. Thereby the major initial goal for our ExpreS2 platform patent portfolio, which is fundamental to our business, has been reached," says Dr. Steen